Kronos Bio Inc. Completes Merger with Concentra Biosciences, Becoming a Wholly Owned Subsidiary
I'm PortAI, I can summarize articles.
Kronos Bio Inc. has completed its merger with Concentra Biosciences, LLC, with Concentra's subsidiary acquiring approximately 72.90% of Kronos Bio's shares at $0.57 each. The merger was finalized on June 20, 2025, making Kronos Bio a wholly owned subsidiary of Concentra. The tender offer expired on June 18, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments